Most Patients Had 5% Weight Loss With Semaglutide. The STEP 1 trial enrolled 1961 adults with a body mass index (BMI) ≥ 30 kg/m 2 or ≥ 27 kg/m 2 with at least one weight-related coexisting ...

In conjunction with lifestyle management, once-weekly semaglutide helped people with obesity lose a significant amount of weight, the Semaglutide Treatment Effect in People with Obesity (STEP) 1 ...

In STEP 1, adults with obesity and without T2D who received semaglutide 2.4 mg had a mean weight loss of 14.9%, which exceeded placebo-based therapy by 12.4%. 17 Although semaglutide 2.4 mg was ...

Superior weight-loss efficacy with the GLP-1 receptor agonist semaglutide demonstrated in the phase 3 STEP studies suggests clinicians have a new opportunity to control obesity and its medical ...

"It's criminal to put someone on a GLP-1 and not put them on a dietary plan," says Phil Vella, founder of Vita Bella Health, ...

STEP 8 randomized 338 US adults without diabetes and a BMI ≥ 27 kg/m 2 plus one or more weight-related comorbidities or a BMI ≥ 30 kg/m 2 3:1 to semaglutide 2.4 mg once weekly (n = 126) or ...

This combination "provided weight loss in the highest range of efficacy observed with existing weight loss interventions," ...

Semaglutide is already available in a 0.5-mg and 1-mg injectable dose sold under the trade name Ozempic, which is indicated for type 2 diabetes and risk reduction of major cardiovascular events ...

Adults with obesity who continued once-weekly semaglutide therapy beyond 20 weeks saw continued weight loss or weight maintenance compared with adults who were switched to placebo, data from the ...